Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.74 - $15.01 $13,315 - $270,089
-17,994 Reduced 52.26%
16,438 $12,000
Q2 2022

Aug 15, 2022

SELL
$0.71 - $2.43 $111,137 - $380,372
-156,532 Reduced 81.97%
34,432 $34,000
Q1 2022

May 16, 2022

BUY
$2.31 - $5.13 $109,671 - $243,557
47,477 Added 33.09%
190,964 $454,000
Q4 2021

Feb 14, 2022

BUY
$4.45 - $8.09 $557,949 - $1.01 Million
125,382 Added 692.53%
143,487 $683,000
Q3 2021

Nov 15, 2021

BUY
$6.94 - $8.85 $119,555 - $152,458
17,227 Added 1962.07%
18,105 $142,000
Q2 2021

Aug 16, 2021

SELL
$7.45 - $16.27 $714,581 - $1.56 Million
-95,917 Reduced 99.09%
878 $7,000
Q1 2021

May 17, 2021

BUY
$8.78 - $12.8 $849,860 - $1.24 Million
96,795 New
96,795 $1.1 Million

About CURIS INC


  • Ticker CRIS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 91,814,704
  • Market Cap $409M
  • Description
  • Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...
More about CRIS
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.